CN Patent

CN119868564A — 一种用于预防和/或治疗肥胖的联合用药物

Assigned to Haichuang Pharmaceutical Co ltd · Expires 2025-04-25 · 1y expired

What this patent protects

本发明属于化学医药领域，具体涉及一种用于预防和/或治疗肥胖的联合用药物。本发明的联合用药物是THR‑β激动剂和GLP‑1受体激动剂的联合用药物。本发明的联合用药物能够协同增效，通过增加脂肪代谢、降低脂肪含量、控制食欲、延缓胃排空、增加饱食感等方面减轻体重，可作为解决肥胖问题的有效策略，具有广阔的应用前景。

USPTO Abstract

本发明属于化学医药领域，具体涉及一种用于预防和/或治疗肥胖的联合用药物。本发明的联合用药物是THR‑β激动剂和GLP‑1受体激动剂的联合用药物。本发明的联合用药物能够协同增效，通过增加脂肪代谢、降低脂肪含量、控制食欲、延缓胃排空、增加饱食感等方面减轻体重，可作为解决肥胖问题的有效策略，具有广阔的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN119868564A
Jurisdiction
CN
Classification
—
Expires
2025-04-25
Drug substance claim
No
Drug product claim
No
Assignee
Haichuang Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.